Search

Displaying results 1211 - 1220 of 3735 in total
  1. Target

    Nuclear receptor subfamily 1 group I member 3

    go.drugbank.com/bio_entities/BE0003848
    TargetHumans

    Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes.

    Polypeptides: Nuclear receptor subfamily 1 group I member 3Synonyms: Orphan nuclear receptor MB67, Constitutive androstane receptor
  2. Target

    Peroxisome proliferator-activated receptor gamma coactivator 1-beta

    go.drugbank.com/bio_entities/BE0009812
    TargetHumans

    Activates transcriptional activity of estrogen receptor alpha, nuclear respiratory factor 1 (NRF1) and glucocorticoid receptor in the presence of glucocorticoids.

    Polypeptides: Peroxisome proliferator-activated receptor gamma coactivator 1-betaSynonyms: PGC-1-related estrogen receptor alpha coactivator
  3. Target

    Leukocyte immunoglobulin-like receptor subfamily B member 2

    go.drugbank.com/bio_entities/BE0010561
    TargetHumans

    Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:11169396, PubMed:12853576, PubMed:16455647, PubMed:20448110, PubMed:27859042).

    Polypeptides: Leukocyte immunoglobulin-like receptor subfamily B member 2Synonyms: Leukocyte immunoglobulin-like receptor 2, Monocyte/macrophage immunoglobulin-like receptor 10
  4. Target

    Leukocyte immunoglobulin-like receptor subfamily B member 1

    go.drugbank.com/bio_entities/BE0010562
    TargetHumans

    Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:16455647, PubMed:28636952). … Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response.

    Polypeptides: Leukocyte immunoglobulin-like receptor subfamily B member 1Synonyms: Leukocyte immunoglobulin-like receptor 1, Monocyte/macrophage immunoglobulin-like receptor 7
  5. Target

    Leukocyte immunoglobulin-like receptor subfamily B member 4

    go.drugbank.com/bio_entities/BE0017129
    TargetHumans

    This inhibition of monocyte activation occurs at least in part via binding to FN1 (PubMed:34089617). … Receptor for apolipoprotein APOE (PubMed:30333625). Receptor for ALCAM/CD166 (PubMed:29263213).

    Polypeptides: Leukocyte immunoglobulin-like receptor subfamily B member 4Synonyms: Monocyte inhibitory receptor HM18, Leukocyte immunoglobulin-like receptor 5
  6. Target

    Mas-related G protein-coupled receptor member X2

    go.drugbank.com/bio_entities/BE0018408
    TargetHumans

    Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (PubMed … Mast cell-specific G protein-coupled receptor for basic secretagogues, which regulates mast cell degranulation and itch-related hypersensitivity reactions (PubMed:22069323, PubMed:25517090, PubMed:28288109

    Polypeptides: Mas-related G protein-coupled receptor member X2Function: C-C chemokine receptor activity
  7. Drug

    Malacidin A

    go.drugbank.com/drugs/DB14051
    Experimental

    Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic analysis. … While structurally similar to other macrocycle drugs like [DB00080] and [DB06087], Malacidin A appears to act via its own distinct mechanism.

  8. Drug

    Malacidin B

    go.drugbank.com/drugs/DB14052
    Experimental

    Malacidins are 10-member macrocycle lipopeptides discovered via gene sequencing and bioinformatic analysis. … While structurally similar to other macrocycle drugs like [DB00080] and [DB06087], Malacidin B appears to act via its own distinct mechanism.

  9. Drug

    MKC1106-PP

    go.drugbank.com/drugs/DB06030
    Experimental

    MKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.). … MKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM.

  10. Indication

    Triple-Negative Breast Cancer

    go.drugbank.com/conditions/DBCOND0068542
    Drugs: Atezolizumab
    Synonyms: Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative